Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30461968 | 1.00 | MAPT (0.50) | MAPTHTTTDP1NPC1RAB9A | |
| SCHEMBL21675477 | 0.86 | MAPT (0.46) | MAPTHTTTDP1NPC1RAB9A | |
| SCHEMBL245209 | 0.85 | MAPT (0.50) | MAPTHTTTDP1NPC1RAB9A | |
| SCHEMBL2962223 | 0.84 | TDP1 (0.57) | MAPTHTTTDP1IDO1ALDH1A1 | |
| SCHEMBL4797007 | 0.82 | IDO1 (0.44) | MAPTHTTTDP1NPC1RAB9A | |
| Propionamide SCHEMBL28511810 | 0.82 | PGR (0.47) | MAPTTDP1NPC1RAB9AALDH1A1 | |
| SCHEMBL18904614 | 0.81 | MAPT (0.46) | MAPTHTTTDP1NPC1RAB9A | |
| SCHEMBL22643737 | 0.81 | MAPT (0.46) | MAPTHTTTDP1NPC1RAB9A | |
| SCHEMBL10393919 | 0.81 | KEAP1 (0.48) | MAPTHTTTDP1NPC1RAB9A | |
| SCHEMBL26385190 | 0.81 | NPC1 (0.48) | MAPTHTTTDP1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3652250-A1 | RESIN COMPOSITION | Hexcel Composites Limited (GB) | 2020-05-20 | — | — | EP | claimed |
| EP-3652244-A1 | RESIN COMPOSITION | Hexcel Composites Limited (GB) | 2020-05-20 | — | — | EP | claimed |
| CN-110914355-A | Resin composition | 赫克塞尔合成有限公司 | 2020-03-24 | — | — | CN | claimed |
| CN-110914363-A | Resin composition | 赫克塞尔合成有限公司 | 2020-03-24 | — | — | CN | claimed |
| CN-110156629-A | The synthetic method of procarbazine | 广州药本君安医药科技股份有限公司 | 2019-08-23 | — | — | CN | claimed |
| WO-2019011984-A1 | RESIN COMPOSITION | HEXCEL COMPOSITES LIMITED (GB) | 2019-01-17 | — | — | WO | claimed |
| WO-2019011982-A1 | RESIN COMPOSITION | HEXCEL COMPOSITES LIMITED (GB) | 2019-01-17 | — | — | WO | claimed |
| WO-2014071194-A2 | METHODS FOR TREATING FIBROMYALGIA | KATZ ROBERT S (US) | 2014-05-08 | — | — | WO | claimed |
| WO-2007016190-A2 | ANTIPARKINSONIAN ACTION OF PHENYLISOPROPYLAMINES | DUKE UNIVERSITY (US) | 2007-02-08 | — | — | WO | claimed |
| US-20070027208-A1 | Antiparkinsonian Action of Phenylisopropylamines | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-02-01 | — | — | US | claimed |
| EP-0469889-B1 | (p-Carbonylaminophenyl)-sulphonyl-nitromethane derivatives | ZENECA LTD (GB) | 1996-01-17 | — | — | EP | claimed |
| US-5189031-A | Inhibitor of enzyme aldose reductase, useful in the treatment of certain peripheral effects of diabetes and galactosemia | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-02-23 | — | — | US | claimed |
| EP-0469889-A1 | (p-Carbonylaminophenyl)-sulphonyl-nitromethane derivatives | ZENECA LIMITED (GB) | 1992-02-05 | — | — | EP | claimed |
| EP-0016581-B1 | ZIEGLER TYPE CATALYST COMPOSITION | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1984-08-08 | — | — | EP | claimed |
| US-20260015455-A1 | EPOXY RESIN COMPOSITION FOR RESIN TRANSFER MOLDING, CURED RESIN PRODUCT, FIBER-REINFORCED COMPOSITE MATERIAL, AND METHOD FOR MANUFACTURING SAME | TORAY INDUSTRIES, INC. (JP) | 2026-01-15 | — | — | US | disclosed |
| CN-119390582-A | Method for continuously producing N-alkylaniline compounds from nitrobenzene compounds and ketones | 浙江工业大学 | 2025-02-07 | — | — | CN | disclosed |
| US-20240117130-A1 | EPOXY RESIN COMPOSITION FOR FIBER-REINFORCED COMPOSITE MATERIAL, FIBER-REINFORCED COMPOSITE MATERIAL, AND METHOD FOR PRODUCING FIBER-REINFORCED COMPOSITE MATERIAL | TORAY INDUSTRIES, INC. (JP) | 2024-04-11 | — | — | US | disclosed |
| EP-0016581-B1 | ZIEGLER TYPE CATALYST COMPOSITION | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1984-08-08 | — | — | EP | disclosed |
| EP-0016581-A1 | Ziegler type catalyst composition | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1980-10-01 | — | — | EP | disclosed |
| US-4224182-A | POLYMERIZATION CATALYSTS | EXXON RESEARCH & ENGINEERING CO. (US) | 1980-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027208-A1 | Antiparkinsonian Action of Phenylisopropylamines | PNMT, SNCA, COMT | MAPT 393/4885HTT 7/4885TDP1 716/4885 |
| US-20260015455-A1 | EPOXY RESIN COMPOSITION FOR RESIN TRANSFER MOLDING, CURED RESIN PRODUCT, FIBER-REINFORCED COMPOSITE MATERIAL, AND METHOD FOR MANUFACTURING SAME | RFT1, RER1, TERB1 | MAPT 1778/4885HTT 2899/4885TDP1 2639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.